<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537497</url>
  </required_header>
  <id_info>
    <org_study_id>B1731013</org_study_id>
    <nct_id>NCT01537497</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers</brief_title>
  <official_title>Phase 1 Four-Arm Parallel Group, Placebo-Controlled Study To Evaluate The Effects Of Single Doses Of PF- 05175157 At Three Dose Levels On Pharmacodynamic And Metabolic Parameters In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate pharmacodynamics of single oral doses of
      PF-05175157 in a dose-dependent fashion in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modulation of carbohydrate and lipid metabolism</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of PF-05175157 after single oral doses</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of PF-05175157 after single oral doses</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of PF-05175157 after single oral doses</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>100 mg PF-05175157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>250 mg PF-05175157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg PF-05175157</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The chance of receiving 100 mg, 250 mg, 600 mg or placebo will be randomized.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.</description>
    <arm_group_label>100 mg PF-05175157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.</description>
    <arm_group_label>250 mg PF-05175157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05175157</intervention_name>
    <description>One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.</description>
    <arm_group_label>600 mg PF-05175157</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.

          -  Healthy is defined as no clinically relevant abnormalities identified by a detailed
             medical history, full physical examination, including blood pressure and pulse rate
             measurement, 12 lead ECG and clinical laboratory tests. In addition, subjects must
             have normal pulmonary function tests and normal ocular findings.

          -  Women must be of non-childbearing potential.

          -  Body Mass Index (BMI) of 19.5 35.5 kg/m2, and a total body weight of &gt; 50 kg (110
             lbs).

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic
             disease (including drug allergies and seasonal allergies at time of dosing).

          -  Evidence or history of any chronic ongoing or current pulmonary disease.

          -  History of smoking in the past 5 years or history or evidence of habitual use of other
             (non smoked) tobacco or nicotine-containing products within 3 months of Screening or
             positive cotinine test at Screening or Day -7.

          -  Active ocular disease including infection, glaucoma, seasonal allergies, dry eye
             symptoms or retinal/optic nerve disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1731013&amp;StudyName=A%20Study%20To%20Evaluate%20The%20Effects%20Of%20PF-05175157%20In%20Healthy%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2012</study_first_submitted>
  <study_first_submitted_qc>February 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>July 6, 2012</last_update_submitted>
  <last_update_submitted_qc>July 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Single Doses</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

